Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY), Merck & Co (NYSE:MRK)

FB Nasdaq FB Facebook

US pharma giant Pfizer (NYSE:PFE) has announced detailed results from OPT Compare (A3921080), a Phase III study of tofacitinib (trade name Xeljanz), the first in a new class of treatment, oral Janus kinase (JAK) inhibitors, the safety and efficacy of which are being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis. Pfizer Inc. (NYSE:PFE) stock performance was -2.14% in last session and finished the day at $31.49. Traded volume was 41,805,152 million shares in the last session and the average volume of the stock remained 25.83 million shares. The beta of the stock remained 0.66. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Gilead Sciences (NASDAQ:GILD) has had a more orderly sell off, but has lost 10 points since March 13. Gilead Sciences, Inc. (NASDAQ:GILD) rose 0.08 percent to $72.13 yesterday on volume of 29.29 million shares. The intra-day range of the stock was $68.81 to $72.89. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $110.95 billion.

Shares of Bristol-Myers Squibb (NYSE:BMY) saw some unusual options trading activity on Monday. Traders bought 10,842 put options on the stock, American Banking & Market News reports. This is an increase of 213% compared to the typical daily volume of 3,464 put options. Bristol-Myers Squibb Co (NYSE:BMY)’s stock on Mar 24, 2014 reported a decrease of -1.96% to the closing price of $51.04. Its fifty two weeks range is $39.18 -$57.49. The total market capitalization recorded $84.57 billion. The overall volume in the last trading session was 19,810,868 million shares. In its share capital, Bristol-Myers Squibb Co (NYSE:BMY) has 1.65 billion outstanding shares.

Endocyte, Inc. and Merck & Co. Inc (NYSE:MRK) announced partnership in April 2012. As part of the partnership agreement, Merck which has already paid $120 million upfront to Endocyte, will pay more than $1 billion to Endocyte if Vynfinit gets approved for treatment of multiple forms of cancer. On Monday, shares of Merck & Co., Inc. (NYSE:MRK) dropped -1.61% to close the day at $53.78. Company return on investment (ROI) is 6.60% and its monthly performance is recorded as -3.27%. Merck & Co., Inc. (NYSE:MRK) quarterly revenue growth is 11.09%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone